An Overview of the Dichotomous Role of Microbiota in Cancer Progression and Management

Overview

Journal Curr Cancer Drug Targets

Publisher Bentham Science Publishers

Specialty Oncology

Date 2024 Feb 27

PMID 38409691

Authors

Pooja Jain

Sradhanjali Mohapatra

Uzma Farooq

Nazia Hassan

Mohd Aamir Mirza

Zeenat Iqbal

Affiliations

Soon will be listed here.

Abstract

It is a well-known fact that cancer is considered the second leading cause of mortality across the globe. Although the human oral cavity and intestine are the natural habitat of thousands of microbes, dysbiosis results in malignancies, such as oral squamous cell carcinoma and colorectal cancer. Amongst the intestinal microbes, is a deadly carcinogen. Also, causative pathogens for the development of pancreatic and colorectal cancer are found in the oral cavity, such as and . Many periodontopathic micro- organisms, like sp., Peptostreptococcus sp., Prevotella sp., Fusobacterium sp., Porphyromonas gingivalis, and Capnocytophaga gingivalis, strongly have an impact on the development of oral cancers. Three basic mechanisms are involved in pathogen-mediated cancer development, like chronic inflammation-mediated angiogenesis, inhibition of cellular apoptosis, and release of carcinogenic by-products. Microbiota has a dichotomous role to play in cancer, i.e., microbiota can be used for cancer management too. Shreds of evidence are there to support the fact that microbiota enhances the chemotherapeutic drug efficacy. This review presents the possible mechanism of the oncogenic effect of microbiota with emphasis on the oral microbiome and also attempts to explain the intricate role of microbiota in cancer management.

References

Montero P, Patel S . Cancer of the oral cavity. Surg Oncol Clin N Am. 2015; 24(3):491-508. PMC: 5018209. DOI: 10.1016/j.soc.2015.03.006. View

Nagy K, Sonkodi I, Szoke I, Nagy E, Newman H . The microflora associated with human oral carcinomas. Oral Oncol. 1998; 34(4):304-8. View

Iida N, Dzutsev A, Stewart C, Smith L, Bouladoux N, Weingarten R . Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013; 342(6161):967-70. PMC: 6709532. DOI: 10.1126/science.1240527. View

Wallace B, Wang H, Lane K, Scott J, Orans J, Koo J . Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 2010; 330(6005):831-5. PMC: 3110694. DOI: 10.1126/science.1191175. View

Richardson M, Ramirez T, Russell N, Moye L . Coley toxins immunotherapy: a retrospective review. Altern Ther Health Med. 1999; 5(3):42-7. View

Zacharski L, Sukhatme V . Coley's toxin revisited: immunotherapy or plasminogen activator therapy of cancer?. J Thromb Haemost. 2005; 3(3):424-7. DOI: 10.1111/j.1538-7836.2005.01110.x. View

Hoption Cann S, van Netten J, van Netten C . Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J. 2004; 79(938):672-80. PMC: 1742910. View

Alexander J, Wilson I, Teare J, Marchesi J, Nicholson J, Kinross J . Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol. 2017; 14(6):356-365. DOI: 10.1038/nrgastro.2017.20. View

Routy B, Gopalakrishnan V, Daillere R, Zitvogel L, Wargo J, Kroemer G . The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol. 2018; 15(6):382-396. DOI: 10.1038/s41571-018-0006-2. View

10.

Routy B, Le Chatelier E, Derosa L, Duong C, Alou M, Daillere R . Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2017; 359(6371):91-97. DOI: 10.1126/science.aan3706. View

11.

Gopalakrishnan V, Spencer C, Nezi L, Reuben A, Andrews M, Karpinets T . Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2017; 359(6371):97-103. PMC: 5827966. DOI: 10.1126/science.aan4236. View

12.

Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M . The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018; 359(6371):104-108. PMC: 6707353. DOI: 10.1126/science.aao3290. View

13.

Patyar S, Joshi R, Byrav D, Prakash A, Medhi B, Das B . Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci. 2010; 17(1):21. PMC: 2854109. DOI: 10.1186/1423-0127-17-21. View

14.

Raman M, Ambalam P, Kondepudi K, Pithva S, Kothari C, Patel A . Potential of probiotics, prebiotics and synbiotics for management of colorectal cancer. Gut Microbes. 2013; 4(3):181-92. PMC: 3669163. DOI: 10.4161/gmic.23919. View

15.

Orlandi E, Iacovelli N, Tombolini V, Rancati T, Polimeni A, De Cecco L . Potential role of microbiome in oncogenesis, outcome prediction and therapeutic targeting for head and neck cancer. Oral Oncol. 2019; 99:104453. DOI: 10.1016/j.oraloncology.2019.104453. View

16.

Parikh A, Puram S, Faquin W, Richmon J, Emerick K, Deschler D . Immunohistochemical quantification of partial-EMT in oral cavity squamous cell carcinoma primary tumors is associated with nodal metastasis. Oral Oncol. 2019; 99:104458. PMC: 7382966. DOI: 10.1016/j.oraloncology.2019.104458. View

17.

Lauritano D, Sbordone L, Nardone M, Iapichino A, Scapoli L, Carinci F . Focus on periodontal disease and colorectal carcinoma. Oral Implantol (Rome). 2017; 10(3):229-233. PMC: 5735383. DOI: 10.11138/orl/2017.10.3.229. View

18.

Galvao-Moreira L, Cruz M . Oral microbiome, periodontitis and risk of head and neck cancer. Oral Oncol. 2015; 53:17-9. DOI: 10.1016/j.oraloncology.2015.11.013. View

19.

Karpinski T . Role of Oral Microbiota in Cancer Development. Microorganisms. 2019; 7(1). PMC: 6352272. DOI: 10.3390/microorganisms7010020. View

20.

Perera M, Al-Hebshi N, Speicher D, Perera I, Johnson N . Emerging role of bacteria in oral carcinogenesis: a review with special reference to perio-pathogenic bacteria. J Oral Microbiol. 2016; 8:32762. PMC: 5039235. DOI: 10.3402/jom.v8.32762. View